Owkin
Information
Owkin was built on the belief that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI to accelerate medical research and drug development. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals.
Owkin has raised over $70M from leading VC funds and is now working with the largest cancer centers and pharmaceutical companies in Europe and in the US. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, PhD, an academic pioneer in the field of Artificial Intelligence in biology.
